Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  London Stock Exchange  >  AstraZeneca PLC    AZN   GB0009895292


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Sterling strengthens vs euro on Brexit talks extension; slips vs stronger dollar

10/26/2020 | 07:28am EST

* Graphic: World FX rates in 2020 http://tmsnrt.rs/2egbfVh

* Graphic: Trade-weighted sterling since Brexit vote http://tmsnrt.rs/2hwV9Hv

LONDON, Oct 26 (Reuters) - Cautious currency markets kept the pound subdued against a stronger dollar on Monday, but it rose slightly against the euro as an extension to Brexit talks gave markets some cause for optimism about a deal being reached before the Dec. 31 deadline.

The dollar strengthened, equities fell and markets were broadly risk-off. Analysts cited new lockdowns in Europe and record-high daily virus cases in the United States, as well as a lack of progress towards a U.S. fiscal stimulus.

The pound found some support from signs of progress in Brexit trade talks. The EU's chief negotiator, Michel Barnier, will be in London until Wednesday to try and clinch a deal, after which negotiations will switch to Brussels.

"Right now there’s a bit of optimism creeping in from the weekend developments - the extension of the talks until Wednesday," said Ned Rumpeltin, head of European currency strategy at TD Securities.

"The fact that France might be signalling some movement on fish is encouraging. We’ll see how that plays out," he said.

The pound rose in early London trading versus the dollar, then fell as the dollar strengthened. At 1606 GMT it was down 0.1% on the day at $1.3027.

Versus the euro - which is considered more indicative of market views on Brexit - the pound was up around 0.2% on the day at 90.74 pence.

Britain and the EU have just over two months left to agree on their future trading relationship, before a Dec. 31 deadline.

There are some hopes that a Brexit deal can be reached, with Ireland's Deputy Prime Minister and Northern Ireland minister Brandon Lewis expressing optimism on Sunday.

Goldman Sachs FX strategists said that Brexit developments were looking positive.

"Despite sterling's underperformance on Friday, we continue to see a path for a sharply higher GBP/USD cross into year-end," they wrote in a note.

Speculators reduced their net short position on the pound in the week to Oct. 20, for the third week running, weekly CFTC futures data showed.

TD Securities' Rumpeltin said that this could be due to a combination of market participants reining in positioning before the U.S. election and that the range of possibilities around Brexit are narrowing.

John Hardy, head of FX strategy at Saxo Bank, wrote in a note to clients that the UK's external deficit and long-term economic scarring from COVID-19 could mean that sterling does not rally as expected if a deal is reached.

"A sterling downside hedge is worth considering here if a deal arrives but fails to spark a rally," he wrote. (Reporting by Elizabeth Howcroft; editing by Emelia Sithole-Matarise, Larry King and Nick Macfie)

© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ASTRAZENECA PLC -2.62% 7729 Delayed Quote.4.34%
BRITISH POUND / US DOLLAR (GBP/USD) -0.04% 1.34457 Delayed Quote.0.81%
All news about ASTRAZENECA PLC
12/03REUTERS SUMMIT-India's economy on the rebound, government focuses on spending..
12/03Canada could approve Pfizer's COVID-19 vaccine within the next week -official..
12/03India's economy on the rebound, government focuses on spending - finance mini..
12/03REUTERS SUMMIT-India's economy on the rebound, government focuses on spending..
12/03ASTRAZENECA : Fortune or foresight? AstraZeneca and Oxford's stories clash on CO..
12/03U.K.'s Covid-19 Vaccine Program to Test Its State-Run Medical System
12/03Merck KGaA agrees research deal with Artios for 'DNA damage' cancer drugs
12/03Merck KGaA agrees research deal with Artios for 'DNA damage' cancer drugs
12/03S.Korea shares close at record high on chip, auto boost
12/03ASTRAZENECA : demonstrates growing leadership in breast cancer at SABCS with dat..
More news
Financials (USD)
Sales 2020 26 494 M - -
Net income 2020 2 998 M - -
Net Debt 2020 13 181 M - -
P/E ratio 2020 43,7x
Yield 2020 2,71%
Capitalization 136 B 137 B -
EV / Sales 2020 5,65x
EV / Sales 2021 4,92x
Nbr of Employees 70 600
Free-Float 95,7%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 122,11 $
Last Close Price 103,98 $
Spread / Highest target 54,0%
Spread / Average Target 17,4%
Spread / Lowest Target -36,5%
EPS Revisions
Pascal Soriot Chief Executive Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Pam P. Cheng Executive VP-Operations & Information Technology
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON2.15%389 985
ROCHE HOLDING AG-3.61%289 019
PFIZER, INC.8.00%226 783
NOVARTIS AG-10.86%207 948
MERCK & CO., INC.-10.03%207 033